Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc.
302, 6 Butler Street
Camberwell, VIC 3124
Australia
61 3 9882 0780
https://www.propanc.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 1
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. James Nathanielsz | Executive Chairman, CEO, CFO, Treasurer & Secretary | 430.28k | N/D | 1974 |
| Dr. Julian Norman Kenyon ChB, M.D., MB | Chief Scientific Officer, CTO & Director | 35.99k | N/D | 1948 |
| Prof. Klaus Kutz | Chief Medical Officer & Member of Scientific Advisory Board | 18.23k | N/D | N/D |
Descripción
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Gestión corporativa
La calificación ISS Governance QuickScore de Propanc Biopharma, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
